BACKGROUND: The goal of this pilot study was to determine the magnitude and direction of intervention effect sizes for inflammatory-related serum markers and relevant health outcomes among breast cancer survivors (BCSs) receiving aphysical activity behavior change intervention compared with usual care. METHODS: This randomized controlled trial enrolled 28 stage I, II, or IIIA BCSs who were post-primary treatment and not regular exercisers. Participants were assigned to either a 3-month physical activity behavior change intervention group (ING) or usual care group (UCG). Intervention included supervised aerobic (150 weekly minutes, moderate-intensity) and resistance (2 sessions per week) exercise that gradually shifted to home-based exercise. Outcomes were assessed at baseline and 3 months. RESULTS:Cardiorespiratory fitness significantly improved in the ING versus the UCG (between-group difference = 3.8 mL/kg/min; d = 1.1; P = .015). Self-reported sleep latency was significantly reduced in the ING versus the UCG (between group difference = -0.5; d = -1.2; P = .02) as was serum leptin (between-group difference = -9.0 ng/mL; d = -1.0; P = .031). Small to medium nonsignificant negative effect sizes were noted for interleukin (IL)-10 and tumor necrosis factor (TNF)-α and ratios of IL-6 to IL-10, IL-8 to IL-10, and TNF-α to IL-10, whereas nonsignificant positive effect sizes were noted for IL-6 and high-molecular-weight adiponectin. CONCLUSIONS: Physical activity behavior change interventions in BCSs can achieve large effect size changes for several health outcomes. Although effect sizes for inflammatory markers were often small and not significant, changes were in the hypothesized direction for all except IL-6 and IL-10.
RCT Entities:
BACKGROUND: The goal of this pilot study was to determine the magnitude and direction of intervention effect sizes for inflammatory-related serum markers and relevant health outcomes among breast cancer survivors (BCSs) receiving a physical activity behavior change intervention compared with usual care. METHODS: This randomized controlled trial enrolled 28 stage I, II, or IIIA BCSs who were post-primary treatment and not regular exercisers. Participants were assigned to either a 3-month physical activity behavior change intervention group (ING) or usual care group (UCG). Intervention included supervised aerobic (150 weekly minutes, moderate-intensity) and resistance (2 sessions per week) exercise that gradually shifted to home-based exercise. Outcomes were assessed at baseline and 3 months. RESULTS:Cardiorespiratory fitness significantly improved in the ING versus the UCG (between-group difference = 3.8 mL/kg/min; d = 1.1; P = .015). Self-reported sleep latency was significantly reduced in the ING versus the UCG (between group difference = -0.5; d = -1.2; P = .02) as was serum leptin (between-group difference = -9.0 ng/mL; d = -1.0; P = .031). Small to medium nonsignificant negative effect sizes were noted for interleukin (IL)-10 and tumor necrosis factor (TNF)-α and ratios of IL-6 to IL-10, IL-8 to IL-10, and TNF-α to IL-10, whereas nonsignificant positive effect sizes were noted for IL-6 and high-molecular-weight adiponectin. CONCLUSIONS: Physical activity behavior change interventions in BCSs can achieve large effect size changes for several health outcomes. Although effect sizes for inflammatory markers were often small and not significant, changes were in the hypothesized direction for all except IL-6 and IL-10.
Authors: Lisa K Sprod; Oxana G Palesh; Michelle C Janelsins; Luke J Peppone; Charles E Heckler; M Jacob Adams; Gary R Morrow; Karen M Mustian Journal: Community Oncol Date: 2010-10
Authors: Bernardine M Pinto; Georita M Frierson; Carolyn Rabin; Joseph J Trunzo; Bess H Marcus Journal: J Clin Oncol Date: 2005-05-20 Impact factor: 44.544
Authors: Wendy Demark-Wahnefried; Elizabeth C Clipp; Miriam C Morey; Carl F Pieper; Richard Sloane; Denise Clutter Snyder; Harvey J Cohen Journal: J Clin Oncol Date: 2006-07-20 Impact factor: 44.544
Authors: Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner Journal: J Proteome Res Date: 2009-01 Impact factor: 4.466
Authors: Jonathan George; Trinitia Cannon; Victor Lai; Luther Richey; Adam Zanation; D Neil Hayes; Carol Shores; Denis Guttridge; Marion Couch Journal: Head Neck Date: 2007-05 Impact factor: 3.147
Authors: Brandon L Pierce; Marian L Neuhouser; Mark H Wener; Leslie Bernstein; Richard N Baumgartner; Rachel Ballard-Barbash; Frank D Gilliland; Kathy B Baumgartner; Bess Sorensen; Anne McTiernan; Cornelia M Ulrich Journal: Breast Cancer Res Treat Date: 2008-04-10 Impact factor: 4.872
Authors: Anne K Swisher; Jame Abraham; Daniel Bonner; Diana Gilleland; Gerald Hobbs; Sobha Kurian; Mary Anne Yanosik; Linda Vona-Davis Journal: Support Care Cancer Date: 2015-03-01 Impact factor: 3.603
Authors: Crystal S Denlinger; Jennifer A Ligibel; Madhuri Are; K Scott Baker; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Lee Jones; Allison King; Grace H Ku; Elizabeth Kvale; Terry S Langbaum; Kristin Leonardi-Warren; Mary S McCabe; Michelle Melisko; Jose G Montoya; Kathi Mooney; Mary Ann Morgan; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Muhammad Raza; Karen L Syrjala; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Nicole McMillian; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2014-05 Impact factor: 11.908
Authors: Si-Woon Park; Ilkyun Lee; Joong Il Kim; Hyuna Park; Jong Doo Lee; Kyeong Eun Uhm; Ji Hye Hwang; Eun Sook Lee; So-Youn Jung; Yong Hyun Park; Ji Youl Lee Journal: Support Care Cancer Date: 2018-08-25 Impact factor: 3.603